IL15 and neoplasm: Additionally, these CAR-T cells achieved greater intratumoral IL-15 concentrations in the PDX tumor model compared to the combination of CAR-T cells and exogenous IL-15 administration, confirming the therapeutic advantage of endogenous IL-15 secretion in preclinical models.